KRAS and metastatic colorectal cancer: Onvansertib is being evaluated in combination with abiraterone and prednisone in adult patients with metastatic castration-resistant prostate cancer (NCT03414034), and in combination with FOLFIRI and bevacizumab in metastatic colorectal cancer patients with a Kras mutation (NCT03829410).